Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2007; 13(7): 1079-1084
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1079
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1079
Figure 2 Profiles of the mean 13CO2 breath excretion (▲) and serum TUDCA concentrations (■) plotted against time.
Data were collected after administration of the Shellac-coated tablet containing 10% w/w of 13C-butyrate and two gelatine capsules containing 250 mg each of TUDCA. Data are expressed as mean ± SD in 12 healthy subjects (A) and 12 Crohn’s disease patients (B).
- Citation: Roda A, Simoni P, Magliulo M, Nanni P, Baraldini M, Roda G, Roda E. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 2007; 13(7): 1079-1084
- URL: https://www.wjgnet.com/1007-9327/full/v13/i7/1079.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i7.1079